STE Stock - STERIS plc
Unlock GoAI Insights for STE
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $5.46B | $5.14B | $4.54B | $4.22B | $3.11B |
| Gross Profit | $2.40B | $2.22B | $1.98B | $1.88B | $1.34B |
| Gross Margin | 44.0% | 43.2% | 43.7% | 44.6% | 43.2% |
| Operating Income | $866.64M | $836.12M | $791.10M | $477.81M | $548.37M |
| Net Income | $614.64M | $378.24M | $107.03M | $243.89M | $397.40M |
| Net Margin | 11.3% | 7.4% | 2.4% | 5.8% | 12.8% |
| EPS | $6.24 | $3.83 | $1.07 | $2.50 | $4.66 |
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The Dental segment provides hand and powered dental instruments, infection control products, personal protective equipment, and water quality products for dental suite. The company serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is based in Dublin, Ireland.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 15th 2025 | Morgan Stanley | Upgrade | Overweight | $276 |
| May 29th 2025 | Jefferies | Initiation | Hold | $263 |
| October 24th 2024 | Piper Sandler | Upgrade | Overweight | $260← $230 |
| February 6th 2024 | KeyBanc Capital Markets | Resumed | Overweight | $253 |
| May 30th 2023 | Morgan Stanley | Initiation | Equal Weight | $206 |
| April 14th 2023 | Piper Sandler | Downgrade | Neutral | $197← $215 |
| September 23rd 2022 | Needham | Downgrade | Hold | - |
| July 14th 2022 | Piper Sandler | Initiation | Overweight | $240 |
| April 7th 2022 | Wolfe Research | Initiation | Outperform | $275 |
Earnings History & Surprises
STEEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 12, 2026 | — | — | — | — |
Q1 2026 | Feb 4, 2026 | $2.55 | — | — | — |
Q4 2025 | Nov 5, 2025 | $2.35 | $2.47 | +5.1% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $2.26 | $2.34 | +3.5% | ✓ BEAT |
Q2 2025 | May 14, 2025 | $2.60 | $2.74 | +5.4% | ✓ BEAT |
Q1 2025 | Feb 5, 2025 | $2.33 | $2.32 | -0.4% | ✗ MISS |
Q4 2024 | Nov 6, 2024 | $2.12 | $2.14 | +0.9% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $1.98 | $2.03 | +2.5% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $2.35 | $2.41 | +2.6% | ✓ BEAT |
Q1 2024 | Feb 7, 2024 | $2.17 | $2.22 | +2.3% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $2.05 | $2.03 | -1.0% | ✗ MISS |
Q3 2023 | Aug 1, 2023 | $1.86 | $2.00 | +7.5% | ✓ BEAT |
Q2 2023 | May 10, 2023 | $2.15 | $2.30 | +7.0% | ✓ BEAT |
Q1 2023 | Feb 8, 2023 | $2.22 | $2.02 | -9.0% | ✗ MISS |
Q4 2022 | Nov 9, 2022 | $2.00 | $1.99 | -0.5% | ✗ MISS |
Q3 2022 | Aug 2, 2022 | $1.90 | $1.90 | 0.0% | = MET |
Q2 2022 | May 11, 2022 | $2.00 | $2.04 | +2.0% | ✓ BEAT |
Q1 2022 | Feb 8, 2022 | $1.95 | $2.12 | +8.7% | ✓ BEAT |
Q4 2021 | Nov 2, 2021 | $1.83 | $1.99 | +8.7% | ✓ BEAT |
Q3 2021 | Aug 9, 2021 | $1.50 | $1.76 | +17.3% | ✓ BEAT |
Latest News
STERIS shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 guidance.
📈 PositiveSteris Raises FY2026 GAAP EPS Guidance from $7.79-$8.04 to $8.04-$8.19 vs $8.05 Est
📈 PositiveSteris Raises FY2026 Adj EPS Guidance from $9.90-$10.15 to $10.15-$10.30 vs $10.09 Est
📈 PositiveSteris Q2 Adj. EPS $2.47 Beats $2.35 Estimate, Sales $1.460B Beat $1.431B Estimate
📈 PositiveFrequently Asked Questions about STE
What is STE's current stock price?
What is the analyst price target for STE?
What sector is STERIS plc in?
What is STE's market cap?
Does STE pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to STE for comparison